2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4181 Low dose IL18 armored CD19 CAR T cells achieve deep remission without lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL: First report of a Phase I clinical trial of 19-28z/IL18 CAR T cells

Jae H Park, MD, Mark Blaine Geyer, MD2, Yannis K. Valtis I, MD3, Elizabeth Miranda4, Elizabeth Cathcart5, Tyler Gunningsmith6, Xiuyan Wang7, Kevin Curran, MD8, Renier Brentjens, MD, PhD9
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

Introduction
CD19 CAR T cell therapy induces high remission rates in relapsed/refractory (R/R) B-acute lymphoblastic leukemia (ALL), yet durable remissions remain limited.  Current CAR-T approaches also require lymphodepleting chemotherapy (LDC), which contributes to prolonged cytopenias, infections, and chemo-related morbidity.  IL18 secreting armored CD19 CAR T cells (19-28z/IL18) were developed to enhance CAR T cell expansion, cytotoxicity, and endogenous immune activation.  In our preclinical B-ALL models, 19-28z/IL18 CAR T cells demonstrated superior anti-leukemic activity without LDC, whereas conventional CAR T cells failed to achieve T-cell expansion in the absence of LDC (Avanzi M et al. Cell Rep 2018).  Although LDC has been incorporated into virtually all clinical CD19 CAR T studies, its necessity for next-generation armored CAR T platforms has not been prospectively evaluated. Here, we report the initial clinical outcomes of the first prospective clinical evaluation of LDC-free 19-28z/IL18 CAR T cells in patients (pts) with R/R B-ALL (NCT06287528).

Methods
Eligible pts included pts ≥17 years old with R/R B-ALL. Prior CD19-directed therapies were allowed. The study has 2 dose levels of 0.5x106 (starting dose) and 0.1x106 CAR T cells/kg (step-down dose). All pts received a single infusion of CAR T cells without LDC.  The primary objectives were to evaluate safety and determine recommended phase 2 dose of CAR T cells.  Secondary objectives were to assess response rates, progress-free survival and persistence of CAR T cells.  Measurable residual disease (MRD) was assessed by multiparameter flow cytometry or ClonoSEQ with a minimum 10-4 sensitivity. 

Results
Six pts have been treated on study.  The median age was 29 yrs old (ranges, 21-31).  Three had Philadelphia chromosome-like ALL, 4 had prior allogeneic SCT, and 3 had prior CD19 CAR T cell therapy.  The median bone marrow blast at treatment was 30% (0.1-99%).  CAR T cells were successfully manufactured in all pts.

Five pts were treated at the starting dose (0.5x106 CAR T cells/kg).  Two pts experienced a transient grade 3 ICANS that lasted <72 hours that met the dose-limiting toxicity (DLT) criteria, and 3 pts experienced grade 2 CRS that resolved <48 hours.  Due to the DLT events in the first 5 pts, the next pt (pt 6) was treated at 0.1x106 CAR T cells/kg and enrollment to that cohort is currently ongoing.  

Among the 6 pts treated to date (5 pts at 0.5x106 and 1 pt at 0.1x106 CAR T cells/kg), 2 pts did not respond, one of whom died of sepsis with active disease. Four pts (67%) achieved MRD negative complete remission (CR), including the last pt treated at the lowest dose level of 0.1x106 CAR T cells/kg, a pt with heterogenous CD19 expression, and 2 pts who had prior brexucabtagene and tisagenlecleucel.  Two of four pts who achieved CR proceeded to allogeneic SCT.  At a median follow-up of 4.4 months (range, 0.5-24), 2 pts experienced disease relapse, both CD19+.  One pt relapsed one year following post-CAR allogeneic SCT and is alive following subsequent treatment including another CD19 CAR T cell therapy; the other pt relapsed with MRD+ disease at month 3 following 19-28z/IL18 and received blinatumomab, regained MRD negative CR and remains alive. 

Notably, robust CAR T cell expansion was observed in all 4 responders, despite not receiving LDC.  The median peak CAR T cell value was 1,131,546 vector copy number (VCN)/ml (ranges, 453,799 – 49,628,297), and the highest expansion occurred in the pt treated at the lowest dose level of 0.1x106 CAR T cells/kg.  This degree of CAR T cell expansion observed without LDC is comparable to the values observed in our prior study of 19-28z CAR (same construct as the study product without IL18) in R/R ALL administered with LDC at a higher dose of 1x106 T cells/kg, where the median peak CAR T cell value was 23,082 VCN/ml (range, 268 – 29,892,388).  Detailed cytokine profiling and endogenous immune activation analysis are ongoing.

Conclusions
Herein we show for the first time that even at low doses, IL18 armored CAR T cells can achieve MRD negative remissions with robust CAR T cell expansion in the absence of LDC in a meaningful cohort of pts. These findings support the hypothesis that enhanced CAR T cell biology can substitute for pharmacologic lymphodepletion, provide the first clinical validation of an LDC-free CAR T approach, and establish a foundation for further investigation of next-generation IL18 armored CAR T cells.

Jae H Park, MD: OncLive - Honoraria; Physician Education Resource - Honoraria; MJH Life Sciences - Honoraria; Autolus - Research Funding; InCyte - Research Funding; Servier - Research Funding; Genentech - Research Funding; Fate Therapeutics - Research Funding; Autolus - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Allogene Therapeutics - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Curocell - Consultancy (Includes expert testimony); Artiva Biotherapeutics - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Caribou Biosicences - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Bright Pharmaceutical Services INC. - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Affyimmune Therapeutics - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)